Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation

Bapineuzumab is a humanized antibody developed by Pfizer and Johnson & Johnson targeting the amyloid (Aβ) plaques that underlie Alzheimer's disease neuropathology. Here we report the crystal structure of a Fab-Aβ peptide complex that reveals Bapineuzumab surprisingly captures Aβ in a monome...

Descripción completa

Detalles Bibliográficos
Autores principales: Miles, Luke A., Crespi, Gabriela A. N., Doughty, Larissa, Parker, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575012/
https://www.ncbi.nlm.nih.gov/pubmed/23416764
http://dx.doi.org/10.1038/srep01302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575012/
https://www.ncbi.nlm.nih.gov/pubmed/23416764
http://dx.doi.org/10.1038/srep01302

Ejemplares similares